N-Acetyl Semax Amidate

NA Semax Amidate · Acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂ · Enhanced Semax

"Semax with two modifications — N-terminal acetylation and C-terminal amidation — that together improve lipophilicity, proteolytic resistance, and blood-brain barrier penetration. The form most community users have switched to from base Semax. Considered more potent per microgram for cognitive effects, with the same BDNF-upregulating, nootropic mechanism but better delivered."

Type

Modified Semax · Ac- + -NH₂ termini

vs base Semax

~2–4× more potent per mcg (community)

Status

UK: not illegal to buy or possess · WADA: not specifically listed · US FDA: not approved · no direct trials on amidate form · inherits Semax data

Route

Intranasal (primary) · SubQ also used

Protocol summary

Community dose

200–600 mcg intranasal

Cycle

5 on / 2 off · 2–4 weeks total

Effect onset

15–30 minutes

Community-reported

200–600 mcg intranasal · 5-on/2-off · 2–4 week cycles · community-preferred over base Semax

No direct human RCTs on this specific amidated form; all efficacy inherits from Semax data

How we read the evidence

Modified Semax variant · superior BBB penetration · base Semax is Russian-approved · NA-Semax-Amidate form is community-derived without trials of its own

Animal evidence

The parent compound (Semax) has substantial preclinical foundation. Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10), developed by Russian neuroscientists in the 1980s. Mechanism: BDNF upregulation in hippocampus and cortex, dopaminergic and serotonergic modulation, neuroprotection via anti-apoptotic pathways. Manchenko et al. 2012 — intranasal and IP Semax improved cognition in healthy rats 15 minutes after treatment. Romanova et al. 2006 — six daily Semax treatments (250 mcg/kg) reduced infarction size and improved performance after photothrombosis. Multiple cerebral ischemia models. Recent 2024 work (Khavinson group) showed Semax and its derivative reduce amyloid load and improve cognition in APP/PS1 transgenic Alzheimer's mice. The N-acetyl-amidated form (Nasemax) inherits this mechanism but has not been tested independently in animal models at the same depth as base Semax.

Community & clinical practice

Standard community protocol: 200–600 mcg intranasal per dose, starting at 200 mcg, 1–2× daily, 5 days on / 2 days off, 2–4 week cycles before longer break. The N-acetyl + C-terminal amide modifications produce a more lipophilic, more proteolytically resistant peptide that community users consistently report as 2–4× more potent per microgram than base Semax for subjective cognitive effects. Cycling addresses the modest tachyphylaxis seen with continuous Semax-family use. Often stacked with Selank for anxiolytic balance (parallel Russian-developed peptide), or with Cerebrolysin for broader neurotrophic support.

Human trial data

Base Semax has substantial Russian clinical evidence across decades — approved on the Russian List of Vital and Essential Drugs (December 2011) for stroke, transient ischemic attack, optic nerve damage, and cognitive disorders. The N-acetyl-amidated form specifically has no published clinical trials of its own — community potency claims are based on subjective user reports across thousands of comparisons, not controlled trials. The Wikipedia and Cognitive Vitality reviews of Semax acknowledge that mechanism of action is incompletely characterised — possibly involving melanocortin receptors, possibly enkephalinase inhibition. Most Russian clinical work is in stroke recovery and cognitive disorders, not healthy-adult cognitive enhancement.

Regulatory status

Base Semax: prescription drug in Russia and Ukraine (decades of clinical use). Not FDA-approved or EMA-approved. Sold as a research peptide in most other markets. The NA-Semax-Amidate form is a research-vendor derivative and has not been formally evaluated by any regulatory agency. WADA does not list Semax-family peptides specifically.

Convergence

Nasemax (N-Acetyl Semax Amidate) inherits a real clinical evidence base (base Semax in Russian medicine) but adds modifications that have not been independently trialled. Community potency claims (~2–4× base Semax) are consistent across user reports but unverified by controlled studies. Standard protocol: 200–600 mcg intranasal, 5-on/2-off, 2–4 week cycles. Pep IQ flags this honestly: the parent compound's evidence base is genuine, the modifications are mechanistically plausible (acetylation + amidation are standard medicinal-chemistry strategies for improving CNS-active peptide PK), but the specific NA-Semax-Amidate form is a community-derived modification without trial-level validation. Among the cleaner nootropic peptides if you accept the evidence framework.

Origin & Background

Why the modifications matter

N-Acetyl Semax Amidate is a chemically modified version of Semax (Met-Glu-His-Phe-Pro-Gly-Pro), the ACTH(4-7) analogue developed at Moscow State University in the 1980s. Base Semax already has a substantial track record — it is approved in Russia for ischaemic stroke, cognitive impairment, and ADHD treatment, with decades of clinical use and a solid Russian literature base.

The two modifications that distinguish NA Semax Amidate from base Semax are: (1) N-terminal acetylation — addition of an acetyl group to the N-terminus, which increases lipophilicity (fat solubility) and protects the peptide from aminopeptidase degradation; and (2) C-terminal amidation — replacement of the free carboxyl group with an amide (-NH₂), which eliminates the charge on the C-terminus, further increasing lipophilicity and reducing proteolytic cleavage by carboxypeptidases.

Together, these modifications produce a more lipophilic, more proteolytically resistant peptide that penetrates the blood-brain barrier more efficiently following intranasal administration. The community consensus — based on thousands of user comparisons over several years — is that NA Semax Amidate produces more noticeable cognitive effects at lower doses than base Semax. Whether this reflects genuinely superior BBB penetration or other pharmacodynamic differences has not been formally studied in human trials.

For the full mechanism, BDNF biology, and Russian clinical history, see the Semax entry in Part Four. This entry focuses specifically on how NA Semax Amidate differs from base Semax and the practical implications of choosing between the two forms. The receptor biology, benefits, and safety profile are substantially shared.

Science & Mechanism

The same BDNF mechanism — better delivered

Mechanism of Action

N-terminal acetylation effects: Acetylation of the N-terminus converts the free amino group (polar, charged) to a neutral, lipophilic acetamide. This (1) increases membrane permeability for passive transcellular diffusion across the blood-brain barrier, (2) protects against aminopeptidase N and dipeptidyl peptidase IV cleavage from the N-terminus, extending half-life, and (3) increases overall peptide stability in nasal secretions and plasma.

C-terminal amidation effects: C-terminal amidation replaces the polar carboxyl group with a neutral amide, mirroring the charge state of many endogenous neuropeptides (which are often naturally amidated at the C-terminus). This reduces proteolytic cleavage by carboxypeptidases, contributes further to lipophilicity, and may improve receptor binding affinity in some peptide systems.

Enhanced intranasal delivery: The nasal mucosa presents a double barrier: the mucus layer (aqueous, favours hydrophilic molecules) and the epithelial membrane (lipid bilayer, favours lipophilic molecules). NA Semax Amidate's increased lipophilicity improves partitioning across the epithelial membrane, while adequate aqueous solubility ensures dissolution in the mucus. The nose-to-brain pathway via olfactory nerves and trigeminal pathways bypasses the BBB entirely for a fraction of the dose.

Same downstream mechanism as base Semax: Once in the CNS, NA Semax Amidate activates the same pathways as Semax — BDNF upregulation in hippocampus and cortex, dopaminergic and serotonergic modulation, neuroprotection via anti-apoptotic pathways, and cognitive enhancement in attention and working memory domains.

Dose comparison vs base Semax: Community experience consistently places NA Semax Amidate as 2–4× more potent per microgram than base Semax for subjective cognitive effects. This means a typical NA Semax Amidate dose of 200–400mcg intranasal is compared to 600–1200mcg of base Semax for equivalent effects. This potency difference has not been confirmed in controlled trials but is remarkably consistent across community reports.

Things to know

Safety — the Semax track record applies

Mild

Nasal irritation — less than base Semax in most reports, but can occur. Use preservative-free intranasal formulations. Rotate nostrils.

Mild

Overstimulation at high doses — anxiety or excessive mental activation at doses above 800mcg in some users. Start low — the potency advantage means less is needed.

Mild

Tolerance with continuous daily use — diminishing effects reported with continuous use beyond 2–3 weeks. Cycle 5 days on / 2 days off, or take regular week-long breaks.